skip to content »

Department of Neurology

Houston, Texas

BCM neurologists see patients through the Baylor Clinic and some of the world's leading specialty clinics.
Department of Neurology
not shown on screen

Poster and Platform Presentations

by ADMDC Members

Faculty > Neurology >

American Academy of Neurology (AAN)
61st Annual Meeting in Seattle, Washington (April 25 - May 2, 2009)

How well does the ADAS-cog measure the spectrum of Alzheimer's disease severity? An item response theory analysis.

Benge J, Balsis S, Geraci L, Massman P, Doody R

Age at onset and pre- morbid IQ influence early progression rates in AD.

Doody R, Chan W, Pavlik V, Massman P, Darby E, Rountree S, Szigeti K

2008 International Conference on Alzheimer's Disease (ICAD)
Chicago, Illinois (July 26-31, 2008)

Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease.

Cummings J, Doody RS, Gavrilova S, Sano M, Aisen P, Seely L, Hung D

Interrater reliability between expert and nonexpert physicians in the assessment of amnestic MCI in the community setting.

Doody RS, Ferris SH, Salloway S, Meuser TM, Murthy AK, Li MC, Goldman R

Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study.

Doody RS, Gavrilova S, Thomas R, Aisen P, Bachurin S, Seely L, Hung D

The effects of donepezil on Alzheimer's disease progression monitored by MRI.

Murthy AK, Schuff N, Suhy J, Doody RS, Goldman R

Persistent antidementia drug treatment and survival in an Alzheimer's disease (AD) cohort.

Rountree S, Pavlik V, Chan W, Doody RS

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Effect of atorvastatin on Alzheimer's disease progression by APOE4 genotype.

Sparks L, Kivipelto M, Doody RS, Waters D, Jones RW, Feldman H, Pickering E, Hu X, Hall S, Breazna A, DeMicco DA, Hey-Hadavi J, Schindler RJ

American Academy of Neurology (AAN)
60th Annual Meeting in Chicago, Illinois (April 12-19, 2008)

Inter-rater reliability between expert and nonexpert physicians in the diagnosis of amnestic MCI in the community setting.

Doody RS, Ferris S, Salloway S, Meuser T, Murthy A, Li MC, Goldman R

Dimebon improves patient function and decreases caregiver assistance time in Alzheimer's disease: One-year clinical trial results.

Doody RS, Gavrilova S, Aisen P, Hirmand M, Sano M

Dimebon improves memory, orientation, language, and praxis in patients with mild to moderate Alzheimer's disease: Results of a one-year placebo-controlled study.

Ferris S, Doody R, Gavrilova S, Sano M, Aisen P, Seely L

Vitamin E use is associated with improved survival in an AD cohort.

Pavlik VN, Doody RS, Rountree SD, Darby EJ

American Neurological Association (ANA)
132nd Annual Meeting in Washington, DC (Oct. 7-10, 2007)

Exposure to anti-dementia drugs slows clinical progression of Alzheimer's disease (AD).

Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Gulley A, Doody RS

Alzheimer's Association International Conference on Prevention of Dementia
Washington, DC (June 9-12, 2007)

Results of a one-year randomized, placebo-controlled trial of dimebon for the treatment of mild to moderate Alzheimer's disease.

Doody R, Garrilova S, Sano M, Thomas R, Aisen P, Bachurin S, Seely L, Hung D

Lipitor's effect in Alzheimer's dementia (LEADe) study: Baseline characteristics.

Jones R, Doody R, Sparks DL, Feldman H, Kivipelto M, Breazna A, Sovei M, DeMicco D, Hey-Hadavi J

Clinical factors associated with the preprogression rate (PPR) in Alzheimer's disease (AD).

Rountree SD, Pavlik VN, Chan W, Darby EJ, Doody RS

The dementia and disability in Thai elderly project: Prevalence of mild cognitive impairment with one-year follow-up and the prevalence of dementia in community-dwelling Thai elderly.

Senanarong V, Hamphadungkit K, Poungvarin N, Cummings J, Doody R

Movement Disorder Society (MDS)
11th International Congress of Parkinson's Disease and Movement Disorders in Istanbul, Turkey (June 3-7, 2007)

Weight change in parkinson and alzheimer patients taking atypical antipsychotic drugs.

Sitburana O, Rountree S, Vuong KD, Ondo W

American Academy of Neurology (AAN)
59th Annual Meeting in Boston, Massachusetts (April 28 - May 5, 2007)

Dimebon improves cognition, function, and behavior in patients with mild- moderate Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled study.

Doody R, Gavrilova S, Sano M, Thomas R, Aisen P, Seely L, Hung D

8th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
Salzburg, Austria (March 14-18, 2007)

Design and baseline data for a study of Lipitor's effect in Alzheimer's disease (LEADe).

Feldman H, Sparks L, Doody R, Kivipelto M, Jones R, Sovel M, Breazna A, Hey-Hadavi J

10th International Conference on Alzheimer's Disease and Related Disorders
Madrid, Spain (July 15-20, 2006)

Predicting progression and survival in Alzheimer's disease.

Doody R, Pavlik V, Massman P, Rountree S, Waring S, Darby E, Chan W

Is functional decline necessary for a diagnosis of Alzheimer's disease?

Park KW, Pavlik VN, Rountree SD, Darby EJ, Doody RS

Clinically presenting mild cognitive impairment (MCI): Variable presentations and their outcomes.

Rountree SD, Waring SC, Chan W, Darby EJ, Doody RS

Preprogression rate, cardiovascular comorbidity, and survival in Alzheimer's disease.

Waring SC, Paranilam JM, Doody RS, Darby EJ, Massman PJ, Chan W

American Academy of Neurology (AAN)
58th Annual Meeting in San Diego, California (April 1-8, 2006)

Predicting progression of Alzheimer's disease.

Doody R, Pavlik V, Massman P, Rountree S, Darby E, Chan W

International Neuropsychological Society (INS)
34th Annual Meeting in Boston, Massachusetts (Feb. 1-4, 2006)

Neuropsychological and demographic correlates of apraxia in a large cohort of Alzheimer's patients.

Acharya D, Massman P, Doody R

Phonemic cued performance on the Boston Naming Test: Longitudinal change and its correlates in Alzheimer's disease.

Benge J, Massman P, Jenkins R, Thornton G, Doody R

Naming improvement with phonemic cues: Which Alzheimer's patients benefit most?

Jenkins R, Massman P, Benge J, Thornton G, Doody R

Category-letter fluency discrepancies in healthy older adults: Normative data and reliability.

Thornton G, Massman P, Benge J, Jenkins R, Doody R

American Neurological Association (ANA)
130th Annual Meeting in San Diego, California (Sept. 25-28, 2005)

Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease.

Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM

2nd Alzheimer's Association International Conference on Prevention of Dementia
Washington, DC (June 9-12, 2005)

Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease.

Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM

Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard-ratio analysis.

Thal LJ, Thomas RG, Grundman M, Bennett DA, Doody RS, Ferris SH, Galasko DR, Jin S, Levey AI, Petersen RC

American Academy of Neurology (AAN)
57th Annual Meeting in Miami Beach, Florida (April 9-16, 2005)

Mild cognitive impairment types and their outcomes.

Issa A, Rountree S, Waring S, Yeh S, Doody RS

ADAS-Cog change rates in MMSE Strata relevant to clinical trials.

Massman P, Doody RS

Relationship of premorbid IQ and education to progression of Alzheimer's disease.

Pavlik V, Doody RS, Massman P, Chan W, Yeh S

European Federation of Neurological Societies (EFNS)
8th Congress in Paris, France (Sept. 4-7, 2004)

Donepezil is safe and well-tolerated in AD patients at doses of up to 20 mg/day.

Schindler R, Corey-Bloom J, Doody R, Zhang R, Leni JR, Li H

Functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.

Wirth Y, Doody RS, Schmitt FA, Mobius HJ, Stoffler A

9th International Conference on Alzheimer's Disease and Related Disorders
Philadelphia, Pennsylvania (July 17-22, 2004)

Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits.

Doody R, Pratt R, Posner H, Kumar D

Longitudinal analysis of the Alzheimer's Disease assessment scale in a large cohort of probable AD patients.

Massman P, Doody R

Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary.

Tariot P, Doody R, Peskind E, Winblad B, Reisberg B, Stoffler A, Graham S, McDonald S

Functional benefits of memantine treatment for patients with moderate to severe Alzhemier's disease.

Wirth Y, Doody RS, Schmitt FA, Mobius HJ

XXIVth Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress
Paris, France (June 20-24, 2004)

Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease.

Wirth Y, Doody R, Schmitt F, Mobius HJ, Stoffler A

American Academy of Neurology (AAN)
55th Annual Meeting in Honolulu, Hawaii (March 29 - April 5, 2003)

Donepezil-treated patients demonstrate global benefits on the Clinician's Interview-Based Impression of Change-Plus version: A comparison of Alzheimer's disease versus vascular dementia.

Doody RS, Pratt RD, Perdomo CA, the Donepezil 307 and 308 vaD Study Groups

Long-term treatment with the NMDA antagonist, memantine: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease.

Ferris SH, Schmitt FA, Doody RS, Moebius H-J, Stoeffler A, Reisberg BJ

8th International Conference on Alzheimer's Disease and Related Disorders
Stockholm, Sweden (July 20-25, 2002)

How well do cerebral spinal fluid tau levels discriminate autopsy confirmed Alzheimer's disease from other dementia diagnoses?

Clark C, Eubank D, Peskind E, Galasko D, Morris J, McKeel D, Farlow M, Weitlauf S, Quinn J, Kaye J, Knopman D, Arai H, Doody R, Decarli C, Leight S, Lee V, Xie S, Trojanowski J

Pathogenesis and treatment strategies for selected therapies under development.

Doody RS

Long term treatment with the NMDA antagonist memantine: results of a 24-week, open label extension study in moderately severe to severe Alzheimer's disease.

Reisberg B, Mobius H, Stoffler A, Schmitt F, Doody R, Ferris S

World Federation of Neurology (WFN)
Research Group on Neuroepidemiology. Regional North American Annual Meeting in Denver, Colorado (April 19, 2002)

Survival in patients with dementia from a large multi ethnic population.

Waring S, Doody RS

American Academy of Neurology (AAN)
53rd Annual Meeting in Philadelphia, Pennsylvania (May 5-11, 2001)

The cognitive benefits of galantamine are sustained for at least 24 months: Results of a longterm extension trial in Alzheimer's disease.

Doody RS, Kershaw P

World Federation of Neurology (WFN)
Research Group on Neuroepidemiology. Regional North American Annual Meeting in Philadelphia, Pennsylvania (May 9, 2001)

Racial differences among patients with Alzheimer's disease from a large multi ethnic population.

Waring S, Doody RS

7th International Conference on Alzheimer's Disease and Related Disorders
Washington, DC (July 9-18, 2000)

Cholinesterase inhibitors: Benefits and limitations.

Doody RS

American Academy of Neurology (AAN)
52nd Annual Meeting in San Diego, California (April 29 - May 6, 2000)

Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a 1-year placebo-controlled functional survival study.

Mohs R, Doody R, Morris J, Ieni J, Perdomo C, Pratt R

Profoundly advanced Alzheimer's disease: Patient characteristics, functional status, disease progression, and care burden.

Sumaira R, Doody R, Lai EC

American Society of Consultant Pharmacists (ASCP)
30th Annual Meeting in St. Loius, Missouri (Nov. 10-13, 1999)

Uninterrupted long-term donepezil treatment results in optimal efficacy with retained safety.

Doody R, Geldmacher DS, Pratt RD, Perdoma CA

European College of Neuropsychopharmacology (ECNP)
12th Congress in London, UK (Sept. 21-25, 1999)

Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year placebo-controlled attrition study.

Mohs R, Doody R, Morris J, Ieni J, Rogers S, Perdomo C, Pratt R

European Neurological Society (ENS)
9th Annual Meeting in Milan, Italy (June 5-9, 1999)

Optimal donepezil efficacy in Alzheimer's disease is dependent on continued administration.

Doody RS, Geldmacher DS, Pratt RD, Perdomo CA

American Academy of Neurology (AAN)
51st Annual Meeting in Toronto, Canada (April 17-24, 1999)

Does ApoE4 correlate with MRI changes in Alzheimer's disease?

Azher S, Doody RS, Haykal H, Dunn JK, Liao T-Y

Clinical benefits of donepezil: Results from a long-term phase III extension trial.

Doody RS, Pratt R, Perdomo C

European College of Neuropsychopharmacology (ECNP)
11th Congress in Paris, France (Oct. 31 - Nov. 4, 1998)

Donepezil improves cognition and global function in Alzheimer's disease: Results from U.S. and multinational phase III clinical trials.

Petit H, Doody RS, Pratt R

6th International Conference on Alzheimer's Disease and Related Disorders
Amsterdam, The Netherlands (July 18-23, 1998)

Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease patients.

Doody RS, Clark C, Farlow M, Foster N, Gonzales N, Liao J, Lai E, Massman P

The presence of APO E4 does not influence rate of decline in Alzheimer's disease.

Kataki M, Doody RS, Liao J, Sims J

Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
Geneva, Switzerland (April 15-18, 1998)

Current therapeutic standards in the treatment of Alzheimer's disease.

Doody RS

Research outcome measures in Alzheimer's disease: Statistical significance, effect size and responder analysis - How do they translate to clinical relevance?

Rogers S, Mohs R, Friedhoff L, Doody RS

American Academy of Neurology (AAN)
49th Annual Meeting in Boston, Massachusetts (April 15-17, 1997)

Outcome measures in dementia trials-video CIBIC validity and reliability.

Quinn JF, Benson DF, Clark C, Doody RS, Jagust W, Knopman D, Kaye J

American College of Neuropsychopharmacology (ACNP)
35th Annual Meeting in San Juan, Puerto Rico (Dec. 9-13, 1996)

Donepezil HCI (E2020) improves cognitive and global function in patients with mild and moderately severe Alzheimer's disease: Results of a 15-week phase III study.

Rogers SL, Doody RS, Mohs RC, Friedhoff LT

International Behavioral Neuroscience Society (ISBN)
5th Annual Meeting in Cancun, Mexico (May 2-5, 1996)

Prevalence of uncontrolled hypertension in a population of Alzheimer's patients.

Kashani A, Doody RS, Wayner MJ, Phelix CF

American Academy of Neurology (AAN)
48th Annual Meeting in San Francisco, California (March 23-30, 1996)

Rate of dementia of the Alzheimer's type (DAT) in subjects with mild cognitive impairment.

Grundman M, Petersen R, Morris J, Ferris S, Sano M, Farlow M, Doody RS, Galasko D, Ernesto C, Thomas R, Thal L, the ADCS Cooperative Study

E-2020 Produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): Results of a 30-week phase III trial.

Rogers S, Doody RS, Mohs R, Friedhoff L

Pharmacologic evidence for autonomic psudomotor dysfunction in patients with Alzheimer's disease.

Sabbagh N, Smith RG, Lynn P, Doody RS, Appel SH, Killian JH

International Neuropsychological Society (INS)
24th Annual Meeting in Chicago, Illinois (Feb. 14-17, 1996)

Reliability and validity of a new clinical global rating scale for Alzheimer's clinical trials.

Olin J, Clark C, Doody RS, Schmitt F, Ferris S, Morris J, Reisberg B, Sneider L

Gerontological Society of America (GSA)
50th Annual Meeting in Los Angeles, California (Nov. 15-19, 1995)

A new clinical global rating scale for Alzheimer's clinical trials.

Olin J, Schneider L, Clark C, Doody RS, Ferris S, Morris J, Reisberg B, Schmitt F

American Neuropsychiatric Association (ANPA)
7th Annual Meeting in Pittsburgh, Pennsylvania (Oct. 12-15, 1995)

Estrogen and psychomotor performance.

Doody RS, Young R, Lynn P, Cooke N, Rosenfield JE

American Academy of Neurology (AAN)
47th Annual Meeting in Seattle, Washington (May 6-13, 1995)

A calculated measure to predict rate of progression in Alzheimer's disease.

Doody RS, Lynn P, Massman PJ

International Neuropsychological Society (INS)
23rd Annual Meeting in Seattle, Washington (Feb. 8-11, 1995)

Sex differences involving naming in Alzheimer's disease: Stronger relationships with left hemisphere functioning in men.

Massman PJ, Doody RS

American Academy of Neurology (AAN)
46th Annual Meeting in Washington, DC (May 1-7, 1994)

Psychometric profiles of Alzheimer's disease (AD) with/without white matter changes compared to subcortical ischemic vascular dementia (IVD).

Doody RS, Massman PJ, Nance ML

Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs.

Massman PJ, Kreiter KT, Jankovic J, Doody RS

International Neuropsychological Society (INS)
22nd Annual Meeting in Cincinnati, Ohio (Feb. 2-5, 1994)

Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease.

Massman PJ, Kreiter KT, Jankovic J, Doody RS

American Neurological Association (ANA)
118th Annual Meeting in Boston, Massachusetts (Oct. 18-20, 1993)

Dysfluency in the speech of AD patients.

Doody RS, Massman P

Literacy and cognition in northern Thailand.

Doody RS, Welsh K

American Society of Human Genetics (ASHG)
43rd Annual Meeting in New Orleans, Louisiana (Oct. 5-9, 1993)

Simulation analysis of a large British pedigree segregating a newly characterized autosomal dominant language disorder: Familial developmental dysphasia.

Dunn W, Doody RS, Gopnik M, Ashizawa T

American Psychiatric Association (APA)
146th Annual Meeting in San Francisco, California (May 22-27, 1993)

Neuroimaging findings and clinical variables associated with psychosis in Alzheimer's disease.

Kotrla K, Chacko R, Jhingran S, Doody RS

International Neuropsychological Society (INS)
21st Annual Meeting in Galveston , Texas (Feb. 24-27, 1993)

Correlates of asymmetric motor speed in Alzheimer's disease.

Massman P, Doody RS

National Academy of Neuropsychology (NAN)
12th Annual Meeting in Pittsburgh, Pennsylvania (Nov. 5-7, 1992)

Neuropsychological correlates of apraxia in Alzheimer's disease patients.

Massman P, Doody RS

American Anthropological Association (AAA)
90th Annual Meeting in Chicago, Illinois (Nov. 20-24, 1991)

Positioning: Neurology and anthropology enabling practices.

Doody RS

American Neurological Association (ANA)
116th Annual Meeting in Seattle, Washington (Sept. 28 - Oct. 2, 1991)

Single photon emission computerized tomography (SPECT) in Alzheimer's disease and multiple-infarct dementia.

Doody RS, Strittmatter WJ, Jhingran S

Establishing the limits of the mini-mental state: MMS "subtests" versus a full neuropsychological battery.

Feher E, Mahurin R, Doody RS, Cooke N, Simms J, Pirozzolo F

Positive and negative psychiatric symptoms in Alzheimer's disease.

Mahurin R, Feher E, Doody RS, Inbody S

American Academy of Neurology (AAN)
43rd Annual Meeting in Boston, Massachusetts (April 21-27, 1991)

The alien hand and related signs.

Doody RS, Jankovic J

American Anthropological Association (AAA)
89th Annual Meeting in New Orleans, Louisiana (Nov. 27 - Dec. 2, 1990)

Sense and nonsense: Dissemination and empiricism in practice.

Doody RS

American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
37th Annual Meeting in Chicago, Illinois (Sept. 7-8, 1990)

Recurrent posterior-type aphasia associated with a seizure focus.

Doody RS, Hrachovy RA

American Academy of Neurology (AAN)
42nd Annual Meeting in Miami, Florida (April 2-4, 1990)

Progressive nonfluent aphasia.

Feher E, Doody RS, Whitehead J, Priozzolo F

American College of Cardiology (ACC)
31st Annual Scientific Session in Atlanta, Georgia (April 25-29, 1982)

Effects of stress management and dietary changes in treating ischemic heart disease.

Ornish DM, Scherwitz LW, Doody RS, et al.